FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149233407> ?p ?o ?g. }

• W2149233407 abstract "Leukemia and lymphoma are generally treated by high-dose chemotherapy and/or radiotherapy. In certain patients, the treatment is consolidated with a transplantation of donor stem cells and immune cells (allogeneic stem cell transplantation). Treatment with chemotherapy and/or radiotherapy is limited by the damage that is afflicted to the healthy tissues of the patients. An improved therapy of hematological malignancies should therefore be specific for malignant cells and spare the healthy cells. Immune therapy and gene therapy are the two most innovative treatment strategies developed over the last years, aiming at a more specific treatment of hematological malignancies. Adoptive immune therapy is the application of donor immune cells (T cells) to a patient, as in allogeneic stem cell transplantation. The donor T cells can track down and eliminate remaining malignant cells in the host (graft-versus-leukemia/lymphoma). Unfortunately, also the healthy tissues of the host can be attacked. This serious and potentially life-threatening complication is called graft-versus-host disease. Through genetic manipulation of T cells in the laboratory before application to the patients, the T cells can be provided with a gene that makes it possible to selectively recognize and eliminate the T cells in case of graft-versus-host disease. This is called suicide gene therapy. Another specific therapy is antibody immune therapy. Antibodies can attach to a specific molecule on the malignant cell and directly kill the cell or activate other immune mechanisms of the body to eliminate the cells. The most famous and successful type is antibody therapy with rituximab directed against the CD20 molecule on the membrane of lymphoma cells. The goal of this thesis is to improve antibody-mediated immune therapy and gene therapy of hematological malignancies by investigation of the human CD20 molecule. The first part describes how retroviral vectors are able to provide donor T cells with the human CD20 gene and how CD20-positive T cells can be eliminated by rituximab. The second part of this thesis demonstrates the direct relationship between the number of CD20 molecules on the cell membrane and the complement-mediated activity of rituximab. In addition, it shows how improved human anti-CD20 antibodies can kill rituximab-resistant cells. An important point concerning the field of gene therapy in general, is safety. It has become clear in the past that the insertion of a vector into the genome of a cell can induce malignant transformation. It will be necessary in the future to protect against this insertional mutagenesis by for instance providing the retroviral vectors with an insulator element or a suicide gene. For anti-CD20 antibody therapy, it can be concluded that the maximum effect of treatment does not seem to be reached. The use of improved second generation antibodies or ways to increase the CD20 expression can lead to a more efficient therapy and may overcome disease resistance. In conclusion, this thesis shows the development of the CD20/anti-CD20 suicide system for adoptive T cell immunotherapy and the investigation of the mechanism of CD20/anti-CD20 antibody therapy. CD20 immuno-gene therapy may lead to a more effective treatment of hematological malignancies." @default.
• W2149233407 created "2016-06-24" @default.
• W2149233407 creator A5043125083 @default.
• W2149233407 date "2008-02-21" @default.
• W2149233407 modified "2023-09-25" @default.
• W2149233407 title "Transfer and targeting of the human CD20 molecule : New perspectives in immuno-gene therapy of hematological malignancies" @default.
• W2149233407 cites W147398146 @default.
• W2149233407 cites W1511416976 @default.
• W2149233407 cites W1529809181 @default.
• W2149233407 cites W1553132954 @default.
• W2149233407 cites W1589026573 @default.
• W2149233407 cites W1637867377 @default.
• W2149233407 cites W1675831178 @default.
• W2149233407 cites W176189142 @default.
• W2149233407 cites W1769569140 @default.
• W2149233407 cites W1780319921 @default.
• W2149233407 cites W1824308746 @default.
• W2149233407 cites W1825768998 @default.
• W2149233407 cites W1854005499 @default.
• W2149233407 cites W1876762588 @default.
• W2149233407 cites W1897592311 @default.
• W2149233407 cites W1898469614 @default.
• W2149233407 cites W1913007537 @default.
• W2149233407 cites W1914229355 @default.
• W2149233407 cites W1915689252 @default.
• W2149233407 cites W1935886040 @default.
• W2149233407 cites W1942856476 @default.
• W2149233407 cites W1952288345 @default.
• W2149233407 cites W1963143659 @default.
• W2149233407 cites W1968772097 @default.
• W2149233407 cites W1969801543 @default.
• W2149233407 cites W1972073735 @default.
• W2149233407 cites W1972843591 @default.
• W2149233407 cites W1974981231 @default.
• W2149233407 cites W1976246831 @default.
• W2149233407 cites W1978410756 @default.
• W2149233407 cites W1979336667 @default.
• W2149233407 cites W1981259148 @default.
• W2149233407 cites W1983339176 @default.
• W2149233407 cites W1984186890 @default.
• W2149233407 cites W1987135399 @default.
• W2149233407 cites W1987746867 @default.
• W2149233407 cites W1988799920 @default.
• W2149233407 cites W1988981936 @default.
• W2149233407 cites W1990463170 @default.
• W2149233407 cites W1991459016 @default.
• W2149233407 cites W1991729875 @default.
• W2149233407 cites W1992900585 @default.
• W2149233407 cites W1993702378 @default.
• W2149233407 cites W1994602646 @default.
• W2149233407 cites W1998609613 @default.
• W2149233407 cites W2003650919 @default.
• W2149233407 cites W2003858277 @default.
• W2149233407 cites W2004459595 @default.
• W2149233407 cites W2004961788 @default.
• W2149233407 cites W2005153747 @default.
• W2149233407 cites W2005245620 @default.
• W2149233407 cites W2005274005 @default.
• W2149233407 cites W2009512645 @default.
• W2149233407 cites W2009586982 @default.
• W2149233407 cites W2009761723 @default.
• W2149233407 cites W2013888495 @default.
• W2149233407 cites W2015250898 @default.
• W2149233407 cites W2017009058 @default.
• W2149233407 cites W2017444975 @default.
• W2149233407 cites W2018518082 @default.
• W2149233407 cites W2020050670 @default.
• W2149233407 cites W2022588086 @default.
• W2149233407 cites W2023705807 @default.
• W2149233407 cites W2024209493 @default.
• W2149233407 cites W2024875691 @default.
• W2149233407 cites W2025128734 @default.
• W2149233407 cites W2025766796 @default.
• W2149233407 cites W2027374210 @default.
• W2149233407 cites W2031813404 @default.
• W2149233407 cites W2033149742 @default.
• W2149233407 cites W2037669641 @default.
• W2149233407 cites W2039215182 @default.
• W2149233407 cites W2043946207 @default.
• W2149233407 cites W2044060373 @default.
• W2149233407 cites W2044360617 @default.
• W2149233407 cites W2047942455 @default.
• W2149233407 cites W2055393026 @default.
• W2149233407 cites W2055443357 @default.
• W2149233407 cites W2058895038 @default.
• W2149233407 cites W2059530009 @default.
• W2149233407 cites W2059533489 @default.
• W2149233407 cites W2060369999 @default.
• W2149233407 cites W2062186653 @default.
• W2149233407 cites W2062321149 @default.
• W2149233407 cites W2062361340 @default.
• W2149233407 cites W2063792914 @default.
• W2149233407 cites W2064541070 @default.
• W2149233407 cites W2065316818 @default.
• W2149233407 cites W2066485964 @default.
• W2149233407 cites W2067016959 @default.
• W2149233407 cites W206701898 @default.
• W2149233407 cites W2067180101 @default.
• W2149233407 cites W2068075049 @default.
• W2149233407 cites W2069524809 @default.

• next